Nipro / 8086 | |
RCoverage Update Notes | Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp |
This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is
available on our websiteand various professional platforms.
On November 9, 2020, Nipro Corporation announced earnings results for 1H FY03/21
Cumulative | FY03/19 | FY03/20 | FY03/21 | FY03/21 | ||||||||||||
(JPYmn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | % of Est. 1H Est. | % of Est. | FY Est. | |||
Sales | 103,201 | 208,325 | 321,312 | 426,399 | 109,761 | 222,668 | 336,721 | 442,516 | 108,925 | 222,254 | 96.8% 229,650 | 49.1% | 452,500 | |||
YoY | 10.3% | 10.9% | 9.3% | 7.8% | 6.4% | 6.9% | 4.8% | 3.8% | -0.8% | -0.2% | 3.1% | 2.3% | ||||
Gross profit | 33,589 | 63,944 | 99,220 | 130,631 | 34,040 | 66,720 | 102,111 | 134,211 | 33,677 | 68,448 | ||||||
YoY | 10.5% | 7.7% | 5.1% | 2.8% | 1.3% | 4.3% | 2.9% | 2.7% | -1.1% | 2.6% | ||||||
GPM | 32.5% | 30.7% | 30.9% | 30.6% | 31.0% | 30.0% | 30.3% | 30.3% | 30.9% | 30.8% | ||||||
SG&A expenses | 26,091 | 51,922 | 78,808 | 106,804 | 27,032 | 53,948 | 82,120 | 107,791 | 26,780 | 53,914 | ||||||
YoY | 7.6% | 8.4% | 7.0% | 6.8% | 3.6% | 3.9% | 4.2% | 0.9% | -0.9% | -0.1% | ||||||
SG&A ratio | 25.3% | 24.9% | 24.5% | 25.0% | 24.6% | 24.2% | 24.4% | 24.4% | 24.6% | 24.3% | ||||||
Operating profit | 7,498 | 12,022 | 20,411 | 23,827 | 7,008 | 12,772 | 19,990 | 26,420 | 6,896 | 14,533 | 121.6% | 11,950 | 54.8% | 26,500 | ||
YoY | 22.0% | 4.6% | -1.8% | -12.0% | -6.5% | 6.2% | -2.1% | 10.9% | -1.6% | 13.8% | -6.4% | 0.3% | ||||
OPM | 7.3% | 5.8% | 6.4% | 5.6% | 6.4% | 5.7% | 5.9% | 6.0% | 6.3% | 6.5% | 5.2% | 5.9% | ||||
Recurring profit | 7,953 | 13,699 | 18,772 | 22,431 | 5,128 | 9,885 | 17,767 | 23,417 | 6,206 | 12,504 | 109.7% | 11,400 | 50.4% | 24,800 | ||
YoY | 27.4% | 16.3% | -6.7% | -1.1% | -35.5% | -27.8% | -5.4% | 4.4% | 21.0% | 26.5% | 15.3% | 5.9% | ||||
RPM | 7.7% | 6.6% | 5.8% | 5.3% | 4.7% | 4.4% | 5.3% | 5.3% | 5.7% | 5.6% | 5.0% | 5.5% | ||||
Net income | 4,682 | 7,615 | 9,852 | 12,136 | 2,792 | 5,886 | 10,858 | -12,281 | 3,029 | 5,473 | 116.4% | 4,700 | 40.5% | 13,500 | ||
YoY | 10.4% | -8.1% | -28.7% | 2.6% | -40.4% | -22.7% | 10.2% | - | 8.5% | -7.0% | -20.1% | - | ||||
Net margin | 4.5% | 3.7% | 3.1% | 2.8% | 2.5% | 2.6% | 3.2% | - | 2.8% | 2.5% | 2.0% | 3.0% | ||||
Quarterly | FY03/19 | FY03/20 | FY03/21 | |||||||||||||
(JPYmn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | ||||||
Sales | 103,201 | 105,124 | 112,987 | 105,087 | 109,761 | 112,907 | 114,053 | 105,795 | 108,925 | 113,329 | ||||||
YoY | 10.3% | 11.4% | 6.6% | 3.5% | 6.4% | 7.4% | 0.9% | 0.7% | -0.8% | 0.4% | ||||||
Gross profit | 33,589 | 30,355 | 35,276 | 31,411 | 34,040 | 32,680 | 35,391 | 32,100 | 33,677 | 34,771 | ||||||
YoY | 10.5% | 4.7% | 0.8% | -4.0% | 1.3% | 7.7% | 0.3% | 2.2% | -1.1% | 6.4% | ||||||
GPM | 32.5% | 28.9% | 31.2% | 29.9% | 31.0% | 28.9% | 31.0% | 30.3% | 30.9% | 30.7% | ||||||
SG&A expenses | 26,091 | 25,831 | 26,886 | 27,996 | 27,032 | 26,916 | 28,172 | 25,671 | 26,780 | 27,134 | ||||||
YoY | 7.6% | 9.2% | 4.5% | 6.0% | 3.6% | 4.2% | 4.8% | -8.3% | -0.9% | 0.8% | ||||||
SG&A ratio | 25.3% | 24.6% | 23.8% | 26.6% | 24.6% | 23.8% | 24.7% | 24.3% | 24.6% | 23.9% | ||||||
Operating profit | 7,498 | 4,524 | 8,389 | 3,416 | 7,008 | 5,764 | 7,218 | 6,430 | 6,896 | 7,637 | ||||||
YoY | 22.0% | -15.4% | -9.6% | -45.9% | -6.5% | 27.4% | -14.0% | 88.2% | -1.6% | 32.5% | ||||||
OPM | 7.3% | 4.3% | 7.4% | 3.3% | 6.4% | 5.1% | 6.3% | 6.1% | 6.3% | 6.7% | ||||||
Recurring profit | 7,953 | 5,746 | 5,073 | 3,659 | 5,128 | 4,757 | 7,882 | 5,650 | 6,206 | 6,298 | ||||||
YoY | 27.4% | 3.8% | -39.2% | 42.6% | -35.5% | -17.2% | 55.4% | 54.4% | 21.0% | 32.4% | ||||||
RPM | 7.7% | 5.5% | 4.5% | 3.5% | 4.7% | 4.2% | 6.9% | 5.3% | 5.7% | 5.6% | ||||||
Net income | 4,682 | 2,933 | 2,237 | 2,284 | 2,792 | 3,094 | 4,972 | -23,139 | 3,029 | 2,444 | ||||||
YoY | 10.4% | -27.4% | -59.6% | - | -40.4% | 5.5% | 122.3% | - | 8.5% | -21.0% | ||||||
Net margin | 4.5% | 2.8% | 2.0% | 2.2% | 2.5% | 2.7% | 4.4% | - | 2.8% | 2.2% |
Source: Shared Research based on company data
Notes: Figures may differ from company materials due to differences in rounding methods.
Sales by quarter | Operating profit by quarter | |||||||||||||||||||||
(JPYmn) | Q1 | Q2 | Q3 | Q4 | (JPYmn) | Q1 | Q2 | Q3 | Q4 | |||||||||||||
500,000 | 426,399 | 442,516 | 452,500 | 35,000 | ||||||||||||||||||
30,000 | ||||||||||||||||||||||
26,420 | 26,500 | |||||||||||||||||||||
400,000 | ||||||||||||||||||||||
105,087 | 105,795 | 23,827 | ||||||||||||||||||||
25,000 | ||||||||||||||||||||||
6,430 | ||||||||||||||||||||||
300,000 | 20,000 | 3,416 | ||||||||||||||||||||
114,053 | ||||||||||||||||||||||
112,987 | ||||||||||||||||||||||
8,389 | 7,218 | |||||||||||||||||||||
15,000 | ||||||||||||||||||||||
200,000 | ||||||||||||||||||||||
112,907 | 113,329 | 7,637 | ||||||||||||||||||||
100,000 | 105,124 | 10,000 | 4,524 | 5,764 | ||||||||||||||||||
5,000 | 7,498 | |||||||||||||||||||||
103,201 | 109,761 | 108,925 | 7,008 | 6,896 | ||||||||||||||||||
0 | ||||||||||||||||||||||
0 | FY03/19 | FY03/20 | FY03/19 | FY03/20 | ||||||||||||||||||
Source: Shared Research based on company data
1/6
RCoverage | Nipro / 8086 | ||||||||||||||
Update Notes | Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp | ||||||||||||||
Quarterly earnings by segment | |||||||||||||||
Cumulative | FY03/19 | FY03/20 | FY03/21 | ||||||||||||
(JPYmn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |||||
Total sales | 103,201 | 208,325 | 321,312 | 426,399 | 109,761 | 222,668 | 336,721 | 442,516 | 108,925 | 222,254 | |||||
YoY | 10.3% | 10.9% | 9.3% | 7.8% | 6.4% | 6.9% | 4.8% | 3.8% | -0.8% | -0.2% | |||||
Medical-Related | 79,257 | 159,686 | 247,883 | 327,359 | 83,732 | 168,216 | 255,874 | 335,767 | 80,954 | 167,536 | |||||
YoY | 14.3% | 14.6% | 12.0% | 9.1% | 5.6% | 5.3% | 3.2% | 2.6% | -3.3% | -0.4% | |||||
% of total sales | 76.8% | 76.7% | 77.1% | 76.8% | 76.3% | 75.5% | 76.0% | 75.9% | 74.3% | 75.4% | |||||
Pharmaceutical-Related | 14,818 | 30,375 | 46,548 | 63,482 | 17,939 | 35,656 | 53,321 | 70,357 | 17,848 | 34,533 | |||||
YoY | -7.5% | -3.2% | 0.5% | -5.0% | 21.1% | 17.4% | 14.6% | 10.8% | -0.5% | -3.1% | |||||
% of total sales | 14.4% | 14.6% | 14.5% | 14.9% | 16.3% | 16.0% | 15.8% | 15.9% | 16.4% | 15.5% | |||||
PharmaPackaging | 9,118 | 18,247 | 26,856 | 35,526 | 9,053 | 18,712 | 27,398 | 36,217 | 10,012 | 19,983 | |||||
YoY | 11.3% | 6.2% | 2.7% | 25.1% | -0.7% | 2.5% | 2.0% | 1.9% | 10.6% | 6.8% | |||||
% of total sales | 8.8% | 8.8% | 8.4% | 8.3% | 8.2% | 8.4% | 8.1% | 8.2% | 9.2% | 9.0% | |||||
Other | 7 | 15 | 23 | 31 | 35 | 81 | 127 | 174 | 110 | 200 | |||||
YoY | 0.0% | 7.1% | 4.5% | 6.9% | 400.0% | 440.0% | 452.2% | 461.3% | 214.3% | 146.9% | |||||
% of total sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | |||||
Operating profit | 7,498 | 12,022 | 20,411 | 23,827 | 7,008 | 12,772 | 19,990 | 26,420 | 6,896 | 14,533 | |||||
YoY | 22.0% | 4.6% | -1.8% | -12.0% | -6.5% | 6.2% | -2.1% | 10.9% | -1.6% | 13.8% | |||||
Medical-Related | 11,134 | 18,959 | 30,852 | 36,722 | 10,534 | 19,178 | 28,859 | 36,249 | 10,157 | 20,485 | |||||
YoY | 42.8% | 15.3% | 11.2% | 0.0% | -5.4% | 1.2% | -6.5% | -1.3% | -3.6% | 6.8% | |||||
OPM | 14.0% | 11.9% | 12.4% | 11.2% | 12.6% | 11.4% | 11.3% | 10.8% | 12.5% | 12.2% | |||||
Pharmaceutical-Related | 2,139 | 4,281 | 7,505 | 10,662 | 3,888 | 6,085 | 8,532 | 13,196 | 3,266 | 5,243 | |||||
YoY | -34.6% | -15.3% | -8.9% | 0.0% | 81.8% | 42.1% | 13.7% | 23.8% | -16.0% | -13.8% | |||||
OPM | 14.4% | 14.1% | 16.1% | 16.8% | 21.7% | 17.1% | 16.0% | 18.8% | 18.3% | 15.2% | |||||
PharmaPackaging | 45 | 323 | 610 | 778 | -5 | 502 | 518 | 675 | 296 | 987 | |||||
YoY | - | 1918.8% | 47.3% | 0.0% | - | 55.4% | -15.1% | -13.2% | - | 96.6% | |||||
OPM | 0.5% | 1.8% | 2.3% | 2.2% | -0.1% | 2.7% | 1.9% | 1.9% | 3.0% | 4.9% | |||||
Other | 33 | 40 | 81 | 146 | 25 | 92 | 128 | 176 | 106 | 193 | |||||
YoY | 266.7% | 53.8% | 92.9% | 94.7% | -24.2% | 130.0% | 58.0% | 20.5% | 324.0% | 109.8% | |||||
OPM | 471.4% | 266.7% | 352.2% | 471.0% | 71.4% | 113.6% | 100.8% | 101.1% | 96.4% | 96.5% | |||||
Adjustments | -5,853 | -11,582 | -18,637 | -24,482 | -7,434 | -13,087 | -18,048 | -23,877 | -6,930 | -12,376 | |||||
Quarterly | FY03/19 | FY03/20 | FY03/21 | ||||||||||||
(JPYmn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |||||
Total sales | 103,201 | 105,124 | 112,987 | 105,087 | 109,761 | 112,907 | 114,053 | 105,795 | 108,925 | 113,329 | |||||
YoY | 10.3% | 11.4% | 6.6% | 3.5% | 6.4% | 7.4% | 0.9% | 0.7% | -0.8% | 0.4% | |||||
Medical-Related | 79,257 | 80,429 | 88,197 | 79,476 | 83,732 | 84,484 | 87,658 | 79,893 | 80,954 | 86,582 | |||||
YoY | 14.3% | 14.9% | 7.5% | 0.9% | 5.6% | 5.0% | -0.6% | 0.5% | -3.3% | 2.5% | |||||
% of total sales | 76.8% | 76.5% | 78.1% | 75.6% | 76.3% | 74.8% | 76.9% | 75.5% | 74.3% | 76.4% | |||||
Pharmaceutical-Related | 14,818 | 15,557 | 16,173 | 16,934 | 17,939 | 17,717 | 17,665 | 17,036 | 17,848 | 16,685 | |||||
YoY | -7.5% | 1.3% | 8.1% | -17.5% | 21.1% | 13.9% | 9.2% | 0.6% | -0.5% | -5.8% | |||||
% of total sales | 14.4% | 14.8% | 14.3% | 16.1% | 16.3% | 15.7% | 15.5% | 16.1% | 16.4% | 14.7% | |||||
PharmaPackaging | 9,118 | 9,129 | 8,609 | 8,670 | 9,053 | 9,659 | 8,686 | 8,819 | 10,012 | 9,971 | |||||
YoY | 11.3% | 1.6% | -3.9% | 283.1% | -0.7% | 5.8% | 0.9% | 1.7% | 10.6% | 3.2% | |||||
% of total sales | 8.8% | 8.7% | 7.6% | 8.3% | 8.2% | 8.6% | 7.6% | 8.3% | 9.2% | 8.8% | |||||
Other | 7 | 8 | 8 | 8 | 35 | 46 | 46 | 47 | 110 | 90 | |||||
YoY | 0.0% | 14.3% | 0.0% | 14.3% | 400.0% | 475.0% | 475.0% | 487.5% | 214.3% | 95.7% | |||||
% of total sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | |||||
Operating profit | 7,498 | 4,524 | 8,389 | 3,416 | 7,008 | 5,764 | 7,218 | 6,430 | 6,896 | 7,637 | |||||
YoY | 22.0% | -15.4% | -9.6% | -45.9% | -6.5% | 27.4% | -14.0% | 88.2% | -1.6% | 32.5% | |||||
Medical-Related | 11,134 | 7,825 | 11,893 | 5,870 | 10,534 | 8,644 | 9,681 | 7,390 | 10,157 | 10,328 | |||||
YoY | 42.8% | -9.5% | 5.3% | - | -5.4% | 10.5% | -18.6% | 25.9% | -3.6% | 19.5% | |||||
OPM | 14.0% | 9.7% | 13.5% | 7.4% | 12.6% | 10.2% | 11.0% | 9.2% | 12.5% | 11.9% | |||||
Pharmaceutical-Related | 2,139 | 2,142 | 3,224 | 3,157 | 3,888 | 2,197 | 2,447 | 4,664 | 3,266 | 1,977 | |||||
YoY | -34.6% | 20.0% | 1.4% | - | 81.8% | 2.6% | -24.1% | 47.7% | -16.0% | -10.0% | |||||
OPM | 14.4% | 13.8% | 19.9% | 18.6% | 21.7% | 12.4% | 13.9% | 27.4% | 18.3% | 11.8% | |||||
PharmaPackaging | 45 | 278 | 287 | 168 | -5 | 507 | 16 | 157 | 296 | 691 | |||||
YoY | - | 54.4% | -27.9% | - | - | 82.4% | -94.4% | -6.5% | - | 36.3% | |||||
OPM | 0.5% | 3.0% | 3.3% | 1.9% | -0.1% | 5.2% | 0.2% | 1.8% | 3.0% | 6.9% | |||||
Other | 33 | 7 | 41 | 65 | 25 | 67 | 36 | 48 | 106 | 87 | |||||
YoY | 266.7% | -58.8% | 156.3% | - | -24.2% | 857.1% | -12.2% | -26.2% | 324.0% | 29.9% | |||||
OPM | 471.4% | 87.5% | 512.5% | 812.5% | 71.4% | 145.7% | 78.3% | 102.1% | 96.4% | 96.7% | |||||
Adjustments | -5,853 | -5,729 | -7,055 | -5,845 | -7,434 | -5,653 | -4,961 | -5,829 | -6,930 | -5,446 |
Source: Shared Research based on company data
Note: Figures may differ from company materials due to differences in rounding methods.
2/6
Nipro / 8086 | |
RCoverage Update Notes | Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp |
1H FY03/21 results (out November 9, 2020)
Overview:
1H FY03/21 (April-September 2020)
▷ | Sales: | JPY222.3bn (-0.2% YoY) |
▷ | Operating profit: | JPY14.5bn (+13.8% YoY) |
▷ | Recurring profit: | JPY12.5bn (+26.5% YoY) |
▷ | Net income*: | JPY5.5bn (-7.0% YoY) |
* Net income attributable to owners of the parent
- Business environment: In the medical devices and pharmaceuticals industry, since the COVID-19 outbreak, patients have continued to cut back on hospital visits while hospitals have reduced outpatient care, and deregulation of online medical consultations progressed.
- Company response: Demand declined for some products used by hospital departments in the Medical-Related business and for contract manufacturing in the Pharmaceutical-Related business. In contrast, demand grew for vaccine-related products, medical containers, and hygiene products such as gloves and masks. As a result, consolidated sales in 1H were only down marginally (-0.2% YoY).
- Operating profit grew 13.8% YoY on lower manufacturing costs and a reduction in expenses due to factors such as restrictions on sales activities, reduced travel, and scaled-back sales promotion activities in efforts to prevent the spread of COVID-19. Recurring profit increased 26.5% YoY on a narrowing in forex losses, while net income fell 7.0% YoY, because the company booked an extraordinary loss relating to a lawsuit filed in the US.
Performance by segment
Medical-Related business
- In 1H FY03/21, sales (to external customers) declined 0.4% YoY to JPY167.5bn.
- Segment profit: JPY20.5bn (+6.8% YoY)
- Domestic sales: Domestic market conditions remain severe because of the COVID-19 outbreak. Although demand remained brisk for hygiene products such as gloves and masks, a decline in outpatient and inpatient care and a substantially lower number of surgical procedures led to a decline in sales of injectable/infusion-related products, enteral nutrition-related products, testing-related products, and vascular-related products. In contrast, sales of implantable mechanical circulatory support were robust among cardiovascular surgical (CVS)-related products, and sales of mainstay dialysis-related products (dialyzers and HDF filters*), which are not as susceptible to adverse effects from the outbreak, held firm. In pharmaceuticals, increased market share of dexmedetomidine and leuprorelin and drugs newly listed in June contributed to sales, but not enough to compensate for depressed sales of antibacterial products due to fewer surgical procedures being performed and promotion of the appropriate use of drugs.
- Overseas sales: The global COVID-19 pandemic made it difficult to engage in aggressive sales activities by attending academic conferences and visiting hospitals. In China, which resumed economic activity ahead of the rest of the world, the company participated in academic conferences to make the Nipro brand better known. The company also benefited from one-time demand for personal protective equipment (PPE) in Latin America and other regions. In 1H FY03/21, the company opened dialysis centers in Chile (Latin America) and China. It plans to set up more centers in Asia and Africa.
- Overseas production facilities: Dialyzer production has been slow at factories in India, where economic activity was restricted nationwide in April 2020 and regionally in July 2020 in response to the spread of COVID-19. It has become difficult to predict prospects for expansion of new production lines scheduled for India. At other production facilities, the Vietnam factory began
3/6
Nipro / 8086 | |
RCoverage Update Notes | Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp |
shipments of blood circuits for dialyzers to Japan in late July 2020. The company plans to utilize the Vietnam factory to increase production capacity and stabilize supply of dialysis-related products.
Pharmaceutical-Related business
- In 1H FY03/21, sales (to external customers) in this business were down 3.1% YoY to JPY34.5bn.
- Segment profit: JPY5.2bn (-3.8% YoY)
- Contract pharmaceutical manufacturing and development: Proposing contract manufacturing of all dosage forms handled by Nipro group, including oral dosage, injectables, and external preparations, and contract manufacturing of drugs at all stages of the development and manufacturing process from investigational new drugs to commercial production, as well as development proposals for use (and packaging as kits) of pharmaceutical containers and delivery systems, for which Nipro has a development and production structure.
- Drug manufacturing: For some products, production lines were revamped to boost capacity, which has delayed deliveries scheduled for Q1. In addition, the COVID-19 outbreak depressed production volumes for some products.
PharmaPackaging business
- In 1H FY03/21, sales (to external customers) were JPY20.0bn (+6.8% YoY).
- Segment profit: JPY987mn (+96.6% YoY)
- The company sought to increase market share in basic medical containers such as vials and ampoules, as well as focusing on promoting the Nipro brand of high-performance products like sterilized syringes and high value-added vials. In manufacturing, the company maintained operations despite the impact of the COVID-19 outbreak, focusing on fulfilling tougher quality requirements and reducing manufacturing costs.
- Overseas sales: Demand for vaccines against COVID-19 was robust, resulting in substantially increased shipments of glass tubing, vials, and sterilized syringes, mainly to Europe and the US. In China, Nipro began deliveries of medical containers that meet global quality standards to a major Chinese vaccine manufacturer.
- Domestic sales: Shipments of medical container-related products such as glass tubing, vials, and rubber stoppers expanded briskly, as did medical device-related products like sponge swabs for COVID-19 antigen test kits.
Other business
- Sales (to external customers) in the Other business in 1H FY03/21 including sales in the real-estate rental business were JPY200mn (+146.9% YoY).
- Segment profit: JPY193mn (+109.8% YoY)
4/6
RCoverage | Nipro / 8086 | |||||||||||||||
Update Notes | Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp | |||||||||||||||
Full-year company forecasts | ||||||||||||||||
FY03/18 | FY03/19 | FY03/20 | FY03/21 | |||||||||||||
(JPYmn) | 1H Act. | 2H Act. | FY Act. | 1H Act. | 2H Act. | FY Act. | 1H Act. | 2H Act. | FY Act. | 1H Act. | 2H Est. | FY Est. | ||||
Sales | 187,903 | 207,494 | 395,397 | 208,325 | 218,074 | 426,399 | 222,668 | 219,848 | 442,516 | 222,254 | 230,246 | 452,500 | ||||
YoY | 5.8% | 13.9% | 9.9% | 10.9% | 5.1% | 7.8% | 6.9% | 0.8% | 3.8% | -0.2% | 4.7% | 2.3% | ||||
Cost of sales | 128,510 | 139,762 | 268,272 | 144,380 | 151,388 | 295,768 | 155,947 | 152,357 | 308,304 | 153,806 | 159,194 | 313,000 | ||||
Gross profit | 59,393 | 67,732 | 127,125 | 63,944 | 66,687 | 130,631 | 66,720 | 67,491 | 134,211 | 68,448 | 71,052 | 139,500 | ||||
GPM | 31.6% | 32.6% | 32.2% | 30.7% | 30.6% | 30.6% | 30.0% | 30.7% | 30.3% | 30.8% | 30.9% | 30.8% | ||||
SG&A expenses | 47,897 | 52,139 | 100,036 | 51,922 | 54,882 | 106,804 | 53,948 | 53,843 | 107,791 | 53,914 | 63,086 | 117,000 | ||||
SG&A ratio | 25.5% | 25.1% | 25.3% | 24.9% | 25.2% | 25.0% | 24.2% | 24.5% | 24.4% | 24.3% | 27.4% | 25.9% | ||||
Operating profit | 11,495 | 15,593 | 27,088 | 12,022 | 11,805 | 23,827 | 12,772 | 13,648 | 26,420 | 14,533 | 11,967 | 26,500 | ||||
YoY | -27.9% | 21.6% | -5.8% | 4.6% | -24.3% | -12.0% | 6.2% | 15.6% | 10.9% | 13.8% | -12.3% | 0.3% | ||||
OPM | 6.1% | 7.5% | 6.9% | 5.8% | 5.4% | 5.6% | 5.7% | 6.2% | 6.0% | 6.5% | 5.2% | 5.9% | ||||
Recurring profit | 11,776 | 10,908 | 22,684 | 13,699 | 8,732 | 22,431 | 9,885 | 13,532 | 23,417 | 12,504 | 12,296 | 24,800 | ||||
YoY | 76.8% | -33.9% | -2.1% | 16.3% | -19.9% | -1.1% | -27.8% | 55.0% | 4.4% | 26.5% | -9.1% | 5.9% | ||||
RPM | 6.3% | 5.3% | 5.7% | 6.6% | 4.0% | 5.3% | 4.4% | 6.2% | 5.3% | 5.6% | 5.3% | 5.5% | ||||
Net income | 8,282 | 3,547 | 11,829 | 7,615 | 4,521 | 12,136 | 5,886 | -18,167 | -12,281 | 5,473 | 8,027 | 13,500 | ||||
YoY | 183.3% | -57.9% | 4.3% | -8.1% | 27.5% | 2.6% | -22.7%-501.8%-201.2% | -7.0% | - | - | ||||||
Net margin | 4.4% | 1.7% | 3.0% | 3.7% | 2.1% | 2.8% | 2.6% | -8.3% | -2.8% | 2.5% | 3.5% | 3.0% |
Source: Shared Research based on company data
Notes: Figures may differ from company materials due to differences in rounding methods.
The company lowered its FY03/21 sales forecast to reflect business conditions in Q2 onward when announcing 1H results on November 9, 2020, but left profit forecasts at all levels more or less unchanged, due in part to improved GPM and expense savings associated with the COVID-19 pandemic. The revised forecast calls for sales of JPY452.5bn (+2.3% YoY), operating profit of JPY26.5bn (+0.3% YoY), recurring profit of JPY24.8bn (+5.9% YoY), and net income attributable to owners of the parent of JPY13.5bn (JPY12.3bn loss in FY03/20).
Planned capital expenditure (acceptance basis [after inspection]) of JPY59.6bn includes JPY35.3bn for the Medical-Related business, JPY18.1bn for the Pharmaceutical-Related business, JPY4.0bn for PharmaPackaging business, and JPY2.2bn for other businesses. Investment for regenerative medicine is included in the capex budget for the Medical-Related business. Depreciation is projected at JPY39.0bn.
Forex rate assumptions are as follows: JPY105/USD, JPY115/EUR, and JPY15.3/CNY. The company assumes yen appreciation for all
three currencies. Forex sensitivity for each currency (annual impact of a one-yen swing in the forex rate) is as follows: for USD, JPY160mn in sales and JPY40mn in operating profit; for EUR, JPY110mn in sales and JPY30mn in operating profit; and for CNY, JPY410mn in sales and JPY130mn in operating profit.
This note is the most recent addition to the full report.
5/6
RCoverage | About Shared Research Inc. | Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp |
We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at https://sharedresearch.jp.
Disclaimer
This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report.
The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.
Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer
The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion from us that could influence investment decisions in the company, such an opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.
Contact Details
Shared Research Inc.
3-31-12 Sendagi Bunkyo-ku Tokyo, Japan
https://sharedresearch.jp
Phone: +81 (0)3 5834-8787
Email: info@sharedresearch.jp
6/6
Attachments
- Original document
- Permalink
Disclaimer
Nipro Corporation published this content on 10 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2020 04:44:02 UTC